Literature DB >> 11965573

Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations.

Scott W Biggins1, Athena Beldecos, John M Rabkin, Hugo R Rosen.   

Abstract

Retransplantation already accounts for 10% of all liver transplants performed, and this percentage is likely to increase as patients live long enough to develop graft failure from recurrent disease. Overall, retransplantation is associated with significantly diminished survival and increased costs. This review summarizes the current causes of graft failure after primary liver transplant, prognostic models that can identify the subset of patients for retransplantation with outcomes comparable to primary transplantation, and ethical considerations in this setting, i.e., outcomes-based versus urgency-based approaches.

Entities:  

Keywords:  Health Care and Public Health

Mesh:

Year:  2002        PMID: 11965573     DOI: 10.1053/jlts.2002.31746

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  10 in total

1.  Futility and rationing in liver retransplantation: when and how can we say no?

Authors:  Scott W Biggins
Journal:  J Hepatol       Date:  2012-02-04       Impact factor: 25.083

Review 2.  Liver transplantation for hepatitis C virus related liver disease.

Authors:  I Gee; G Alexander
Journal:  Postgrad Med J       Date:  2005-12       Impact factor: 2.401

3.  Liver retransplantation in adults: a single-centre, 25-year experience.

Authors:  Ravi Marudanayagam; Vivekanandan Shanmugam; Bynvant Sandhu; Bridget K Gunson; Darius F Mirza; David Mayer; John Buckels; Simon R Bramhall
Journal:  HPB (Oxford)       Date:  2010-04       Impact factor: 3.647

4.  Identifying independent risk factors for graft loss after primary liver transplantation.

Authors:  Jill Gwiasda; Harald Schrem; Jürgen Klempnauer; Alexander Kaltenborn
Journal:  Langenbecks Arch Surg       Date:  2017-06-01       Impact factor: 3.445

5.  Short- and long-term outcomes of third liver transplantation at single centre.

Authors:  Hideya Kamei; Mamoun Al-Basheer; Jeffrey Shum; Michael Bloch; Roberto Hernandez Alejandro; Vivian McAlister; William Wall; Douglas Quan
Journal:  Hepatol Int       Date:  2012-03-14       Impact factor: 6.047

6.  Survival benefit of repeat liver transplantation in the United States: a serial MELD analysis by hepatitis C status and donor risk index.

Authors:  S W Biggins; J Gralla; J L Dodge; K M Bambha; S Tong; A E Barón; J Inadomi; N Terrault; H R Rosen
Journal:  Am J Transplant       Date:  2014-09-19       Impact factor: 8.086

7.  Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice.

Authors:  Gorden Muduma; Isaac Odeyemi; Richard Fulton Pollock
Journal:  Drugs Real World Outcomes       Date:  2016-03

8.  Primary liver transplantation and liver retransplantation: comparison of health-related quality of life and mental status - a cross-sectional study.

Authors:  Johannes Broschewitz; Georg Wiltberger; Nicco Krezdorn; Felix Krenzien; Julia Förster; Georgi Atanasov; Hans-Michael Hau; Moritz Schmelzle; Andreas Hinz; Michael Bartels; Christian Benzing
Journal:  Health Qual Life Outcomes       Date:  2017-07-21       Impact factor: 3.186

9.  Liver retransplantation in adults: the largest multicenter Italian study.

Authors:  Umberto Maggi; Enzo Andorno; Giorgio Rossi; Luciano De Carlis; Umberto Cillo; Fabrizio Bresadola; Vincenzo Mazzaferro; Andrea Risaliti; Paolo Bertoli; Dario Consonni; Francesco Barretta; Tullia De Feo; Mario Scalamogna
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

10.  The PRAISE study: a prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of iloprost in the early postoperative period after liver transplantation (ISRCTN12622749).

Authors:  Erik Bärthel; Falk Rauchfuss; Heike Hoyer; Maria Breternitz; Karin Jandt; Utz Settmacher
Journal:  BMC Surg       Date:  2013-01-29       Impact factor: 2.102

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.